US Markets

Regeneron's Ebola treatment proves superior to rival in trial

Credit: REUTERS/Baz Ratner

Regeneron Pharmaceuticals Inc said on Monday its experimental treatment for Ebola proved superior to a rival therapy from Mapp Biopharmaceutical at preventing death, in a trial evaluating four treatments for infections caused by the deadly virus.

Aug 12 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O said on Monday its experimental treatment for Ebola proved superior to a rival therapy from Mapp Biopharmaceutical at preventing death, in a trial evaluating four treatments for infections caused by the deadly virus.

The company said the trial was ended early because its therapy, REGN-EB3, elicited a "highly statistically significant result" compared to Mapp's ZMapp, which was considered a standard-of-care treatment.

An independent data safety monitoring board ended the trial after reviewing interim mortality data from 499 patients, Regeneron said.

(Reporting by Tamara Mathias in Bengaluru; Editing by Shinjini Ganguli)

((Tamara.Mathias@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 806749 1208;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest Markets Videos

    Reuters

    Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

    Learn More